Code Today, the medical series announced on Thursday that it was suspending the vaccine against the Govit-19 vaccine from AstraZeneca. Reuters reports that many of those who were initially vaccinated developed blood clots.


The vaccine is documented to be safe and effective. However, Sren Prostrom, director of the State Health Council, told a news conference on the day of the press conference that we must first respond to various external incidents recorded in Denmark and other European countries.

In recent days, Austria has pointed to a number of problems with the Austrienega vaccine. One country grew up after a nurse who was vaccinated from a hospital in Svetl died of external thrombosis, another was in a state of pulmonary embolism. However, the European Pharmaceuticals Association (EMA) announced on Wednesday that the vaccine replacement was based on an initial assessment of horse shoes. Therefore, according to the EMA, shelter is not the reason for health needs from Austria.

The vaccine, developed by the British-German company AstraZeneca in collaboration with the University of Oxford, has been recommended by EMA for conditional use in EU countries in Norway and is expected to be used in the Czech Republic. In addition to N, Pfizer / Bioentech and Modernna vaccine companies.

Some of them also decided not to vaccinate AstraZeneca over the age of 65 years. The reason was that it was relatively low according to the elderly included in the clinical studies, so the data were mainly about the performance of their age groups. AstraZeneca speculates about the low activity of the vaccine in the elderly.

READ  Formula 1 at Silverstone: How do the new sprint races work?


LEAVE A REPLY

Please enter your comment!
Please enter your name here